Mark M Moasser Selected Research

Mark M Moasser Research Topics

Disease

32	Neoplasms (Cancer) 01/2023 - 10/2003
7	Breast Neoplasms (Breast Cancer) 02/2016 - 06/2004
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2019
2	Carcinogenesis 04/2011 - 04/2009
1	Hyperglycemia 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Arthritis (Polyarthritis) 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Multiple Sclerosis 01/2017
1	Obesity 10/2014
1	Neutropenia 09/2009
1	Vomiting 09/2009
1	Embolism (Embolus) 04/2005
1	Disease Progression 04/2005
1	Neoplasm Metastasis (Metastasis) 04/2005
1	Exanthema (Rash) 06/2004
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2003
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 04/2003
1	Blast Crisis (Blast Phase) 04/2003

Drug/Important Bio-Agent (IBA)

10	Phosphotransferases (Kinase)IBA 01/2022 - 06/2004
9	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2007
5	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 06/2004
5	Lapatinib (GW572016)FDA Link 01/2021 - 09/2009
4	src-Family KinasesIBA 01/2021 - 08/2005
4	Tyrosine Kinase InhibitorsIBA 01/2010 - 01/2007
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
3	Trastuzumab (Herceptin)FDA Link 02/2016 - 06/2004
2	tyrosine receptor (receptor, tyrosine)IBA 01/2023 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2015
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 12/2008
2	Epidermal Growth Factor (EGF)IBA 01/2020 - 12/2008
2	Mechanistic Target of Rapamycin Complex 2IBA 12/2015 - 12/2015
2	human ERBB2 proteinIBA 11/2015 - 01/2010
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2010 - 03/2010
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2008 - 10/2003
2	AnthracyclinesIBA 04/2008 - 04/2005
2	Gefitinib (Iressa)FDA Link 12/2007 - 10/2003
1	Protein Kinases (Protein Kinase)IBA 01/2023
1	AlpelisibIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	PlatinumIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	SEC Translocation ChannelsIBA 01/2021
1	coibamide AIBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2018
1	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 01/2017
1	LigandsIBA 01/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2016
1	IntegrinsIBA 02/2016
1	MK 2206IBA 02/2016
1	pertuzumabIBA 11/2015
1	Hormones (Hormone)IBA 10/2014
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2010
1	Mitogen-Activated Protein KinasesIBA 01/2010
1	Sirolimus (Rapamycin)FDA Link 01/2010
1	Albumin-Bound Paclitaxel FDA Link 09/2009
1	130-nm albumin-bound paclitaxelIBA 09/2009
1	Oncogene Proteins (Oncogene Protein)IBA 04/2009
1	Bevacizumab (Avastin)FDA Link 12/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2008
1	Taxoids (Taxanes)IBA 04/2008
1	Growth Factor ReceptorsIBA 12/2007
1	taxaneIBA 04/2005
1	Gemcitabine FDA Link 04/2005
1	cyclo(Arg-Pro) (CI 4)IBA 04/2005
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 06/2004
1	Celecoxib (Celebrex)FDA Link 06/2004
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2003
1	bcr-abl Fusion ProteinsIBA 04/2003
1	pyrimidineIBA 04/2003
1	Imatinib Mesylate (Gleevec)FDA Link 04/2003

Therapy/Procedure

17	Therapeutics 01/2023 - 12/2007
2	Drug Therapy (Chemotherapy) 11/2015 - 09/2009
1	Combination Drug Therapy (Combination Chemotherapy) 12/2015